Company profile
ATYR PHARMA INC
NASDAQ:ATYRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EFZOFITIMOD | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05415137 | phase3 | completed | 2022-09-15 | 2025-06-25 | aTyr Pharma, Inc. | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis |
| NCT02603562 | phase1_2 | completed | 2016-03-30 | 2016-12-12 | aTyr Pharma, Inc. | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy |
| NCT02579239 | phase1_2 | completed | 2015-11-30 | 2016-10-05 | aTyr Pharma, Inc. | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) |
| NCT02531217 | phase1_2 | completed | 2015-08-13 | 2016-05-26 | aTyr Pharma, Inc. | Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension |
| NCT02239224 | phase1_2 | completed | 2014-09-04 | 2015-12-14 | aTyr Pharma, Inc. | Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy |
FDA applications (0)
No records yet.